(OCGN) – Hot FDA News
-
Ocugen (OCGN) Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400
-
Ocugen (OCGN) Reports Positive Phase 2/3 Top-Line Data for COVAXIN
-
-
-
-
-
-
-
-
-
-
-
-
Back to OCGN Stock Lookup